ABSTRACT
Objective Autoantibodies are clinically useful in phenotyping patients with systemic sclerosis (SSc). GI function is regulated by the enteric nervous system (ENS) and commonly impaired in SSc suggesting that the SSc autoimmune response may target ENS antigens. We sought to identify novel anti-ENS autoantibodies with an aim to clinically phenotype SSc GI dysfunction.
Methods Serum from a SSc patient with GI dysfunction but without defined SSc-associated autoantibodies was used for autoantibody discovery. Immunoprecipitations performed with murine myenteric plexus lysates were on-bead digested and autoantigens were identified by mass spectrometry. Prevalence and clinical features associated with novel autoantibodies were evaluated in a SSc cohort using regression analyses. Expression of gephyrin in human GI tract tissue was examined by immunohistochemistry.
Results We identified gephyrin as a novel SSc autoantigen. Anti-gephyrin antibodies were present in 9% of SSc patients (16/188) and absent in healthy controls (0/46). Anti-gephyrin antibody-positive patients had higher constipation scores [1.00 vs. 0.50;p=0.02] and were more likely to have severe constipation and severe distention/bloating [46% vs. 15%;p=0.005; 54% vs. 25%;p=0.023, respectively]. Anti-gephyrin antibody levels were significantly higher among patients with severe constipation [0.04 vs. 0.00;p=0.001] and severe distention and bloating [0.03 vs. 0.004;p=0.010]. Severe constipation was associated with anti-gephyrin antibodies even in the adjusted model. Importantly, gephyrin was expressed in the ENS, which regulates gut motility.
Conclusion Gephyrin is a novel ENS autoantigen that is expressed in human myenteric ganglia. Anti-gephyrin autoantibodies are associated with the presence and severity of constipation in SSc patients.
Competing Interest Statement
The authors have declared no competing interest.
Funding Statement
NIH/NIAMS K23 AR071473 to ZM; Scleroderma Research Foundation to FMW and ZM; Rheumatology Research Foundation K Supplement and Jerome L Greene Foundation to ZM; the Martha McCrory Professorship to FMW; Chresanthe Stauraluakis Memorial Discovery Fund to JHSC; NIH grants R01 AR073208 to LCR, P30-AR070254 to AR and JP, R01 AR069569 to FA, R01AG66768 to SK. The mass spectrometry was performed at the JHU School of Medicine Mass Spectrometry and Proteomics Core Facility. Microscopy was performed by the Ross Confocal Facility at JHU School of Medicine, which was supported by the NIH shared instrumentation grant 1S10OD025244-01 for the Olympus FV3000RS confocal microscope.
Author Declarations
I confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.
Yes
The details of the IRB/oversight body that provided approval or exemption for the research described are given below:
The Johns Hopkins Institutional Review Board approved all human subjects protocols used, and all individuals provided informed consent. Human autopsy specimen use was approved by the Johns Hopkins Institutional Review Board. These were collected through the Johns Hopkins Legacy Gift Rapid Autopsy program.
I confirm that all necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived, and that any patient/participant/sample identifiers included were not known to anyone (e.g., hospital staff, patients or participants themselves) outside the research group so cannot be used to identify individuals.
Yes
I understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).
Yes
I have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.
Yes
Footnotes
Funding Statement: NIH/NIAMS K23 AR071473 to ZM; Scleroderma Research Foundation to FMW and ZM; Rheumatology Research Foundation K Supplement and Jerome L Greene Foundation to ZM; the Martha McCrory Professorship to FMW; Chresanthe Stauraluakis Memorial Discovery Fund to JHSC; NIH grants R01 AR073208 to LCR, P30-AR070254 to AR and JP, R01 AR069569 to FA, R01AG66768 to SK. The mass spectrometry was performed at the JHU School of Medicine Mass Spectrometry and Proteomics Core Facility. Microscopy was performed by the Ross Confocal Facility at JHU School of Medicine, which was supported by the NIH shared instrumentation grant 1S10OD025244-01 for the Olympus FV3000RS confocal microscope.
Conflict of interest statement: None of the authors received any financial support or other benefits from commercial sources for the work reported in this manuscript, nor do any of the authors have any financial interests, which could create a potential conflict of interest or appearance thereof.
Data Availability
All data produced in the present study are available upon reasonable request to the authors.
